Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?

Cancers

Volumn 6, Issue 2, 2014, Pages 684-707

  Turner, Natalie ^a   Pestrin, Marta ^a,b   Galardi, Francesca ^b   De Luca, Francesca ^b   Malorni, Luca ^a,b   Di Leo, Angelo ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b HOSPITAL OF PRATO   (Italy)

Author keywords

Anti HER2 therapy; Biomarker; Breast cancer; Cellsearch; Chemotherapy; Circulating tumor cells; HER2; Liquid biopsy; Metastatic; Predictive biomarker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN PIK3CA; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANALYZER; APOPTOSIS; BIOPSY TECHNIQUE; BLOOD EXAMINATION; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CELL HETEROGENEITY; CELL ISOLATION; CHEMOSENSITIVITY; CIRCULATING TUMOR CELL; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; GENE MUTATION; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; INTERVENTIONAL RADIOLOGY; LEUKOCYTE COUNT; METASTASIS POTENTIAL; MOLECULAR DIAGNOSIS; PIK3CA GENE; PREDICTIVE VALUE; PRIMARY TUMOR; PROTEIN EXPRESSION; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

EID: 84897087080     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6020684     Document Type: Review

References (94)

1. National Cancer Institute Surveillance, Epidemiology and End Results: Breast cancer incidence and mortality. Available online: www.seer.gov/statfacts/html/breast.html (accessed on 11 August 2013).
2. Cancer Research UK breast cancer incidence statistics. Available online: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/(accessed on 11 August 2013).
3. Brewster, A.M.; Hortobagyi, G.N.; Broglio, K.R.; Kau, S.W.; Santa-Maria, C.A.; Arun, B.; Buzdar, A.U.; Booser, D.J.; Valero, V.; Bondy, M., et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J. Natl. Cancer Inst. 2008, 100, 1179-1183.
4. Gupta, G.P.; Massague, J. Cancer metastasis: Building a framework. Cell 2006, 127, 679-695.
5. Valastyan, S.; Weinberg, R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011, 147, 275-292.
6. Ashworth, T.R. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 1869, 14, 146-149.
7. Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351, 781-791.
8. Dawood, S.; Broglio, K.; Valero, V.; Reuben, J.; Handy, B.; Islam, R.; Jackson, S.; Hortobagyi, G.N.; Fritsche, H.; Cristofanilli, M. Circulating tumor cells in metastatic breast cancer: From prognostic stratification to modification of the staging system? Cancer 2008, 113, 2422-2430.
9. Hayes, D.F.; Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Miller, M.C.; Matera, J.; Allard, W.J.; Doyle, G.V.; Terstappen, L.W. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 2006, 12, 4218-4224.
10. Zhang, L.; Riethdorf, S.; Wu, G.; Wang, T.; Yang, K; Peng, G.; Liu, J.; Pantel, K. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 2012, 18, 5701-5710.
11. Bidard, F.C.; Vincent-Salomon, A.; Sigal-Zafrani, B.; Dieras, V.; Mathiot, C.; Mignot, L.; Thiery, J.P.; Sastre-Garau, X.; Pierga, J.Y. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann. Oncol. 2008, 19, 496-500.
12. Pierga, J.Y.; Hajage, D.; Bachelot, T.; Delaloge, S.; Brain, E.; Campone, M.; Dieras, V.; Rolland, E.; Mignot, L.; Mathiot, C., et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. 2012, 23, 618-624.
13. Rack, B.; Schindlbeck, C.; Andergassen, A.; Schneeweiss, A.; Zwingers, T.; Lichtenegger, W.; Beckmann, M.; Sommer, H.; Pantel, K.; Janni, W. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk of relapse: The SUCCESS trial. J. Clin. Oncol. 2010, 28, Abstract No. 1003.
14. Tewes, M.; Aktas, B.; Welt, A.; Mueller, S.; Hauch, S.; Kimmig, R.; Kasimir-Bauer, S. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: An option for monitoring response to breast cancer related therapies. Breast Cancer Res. Treat. 2009, 115, 581-590.
15. Martin, M.; Custodio, S.; de Las Casas, M.L.; Garcia-Saenz, J.A.; de la Torre, J.C.; Bellon-Cano, J.M.; Lopez-Tarruella, S.; Vidaurreta-Lazaro, M.; de la Orden, V.; Jerez, Y., et al. Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer. Oncologist 2013, 18, 917-923.
16. Budd, G.T.; Cristofanilli, M.; Ellis, M.J.; Stopeck, A.; Borden, E.; Miller, M.C.; Matera, J.; Repollet, M.; Doyle, G.V.; Terstappen, L.W., et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 2006, 12, 6403-6409.
17. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
18. Turner, N.H.; di Leo, A. HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact. Cancer Treat. Rev. 2013, 39, 947-957.
19. Amir, E.; Miller, N.; Geddie, W.; Freedman, O.; Kassam, F.; Simmons, C.; Oldfield, M.; Dranitsaris, G.; Tomlinson, G.; Laupacis, A., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 2012, 30, 587-592.
20. Thompson, A.M.; Jordan, L.B.; Quinlan, P.; Anderson, E.; Skene, A.; Dewar, J.A.; Purdie, C.A. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: The Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010, 12, R92.
21. Riethdorf, S.; Fritsche, H.; Muller, V.; Rau, T.; Schindlbeck, C.; Rack, B.; Janni, W.; Coith, C.; Beck, K.; Janicke, F., et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin. Cancer Res. 2007, 13, 920-928.
22. Kraan, J.; Sleijfer, S.; Strijbos, M.H.; Ignatiadis, M.; Peeters, D.; Pierga, J.Y.; Farace, F.; Riethdorf, S.; Fehm, T.; Zorzino, L., et al. External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study. Cytom. B Clin. Cytom. 2011, 80, 112-118.
23. Mostert, B.; Sleijfer, S.; Foekens, J.A.; Gratama, J.W. Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer. Cancer Treat. Rev. 2009, 35, 463-474.
24. Talasaz, A.H.; Powell, A.A.; Huber, D.E.; Berbee, J.G.; Roh, K.H.; Yu, W.; Xiao, W.; Davis, M.M.; Pease, R.F.; Mindrinos, M.N., et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc. Natl. Acad. Sci. USA 2009, 106, 3970-3975.
25. Allan, A.L.; Keeney, M. Circulating tumor cell analysis: Technical and statistical considerations for application to the clinic. J. Oncol. 2010, 2010, e426218.
26. Mostert, B.; Kraan, J.; Bolt-de Vries, J.; van der Spoel, P.; Sieuwerts, A.M.; Schutte, M.; Timmermans, A.M.; Foekens, R.; Martens, J.W.; Gratama, J.W., et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res. Treat. 2011, 127, 33-41.
27. Bednarz-Knoll, N.; Alix-Panabieres, C.; Pantel, K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012, 31, 673-687.
28. Naume, B.; Borgen, E.; Tossvik, S.; Pavlak, N.; Oates, D.; Nesland, J.M. Detection of isolated tumor cells in peripheral blood and in BM: Evaluation of a new enrichment method. Cytotherapy 2004, 6, 244-252.
29. Gertler, R.; Rosenberg, R.; Fuehrer, K.; Dahm, M.; Nekarda, H.; Siewert, J.R. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res. 2003, 162, 149-155.
30. Desitter, I.; Guerrouahen, B.S.; Benali-Furet, N.; Wechsler, J.; Janne, P.A.; Kuang, Y.; Yanagita, M.; Wang, L.; Berkowitz, J.A.; Distel, R.J., et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 2011, 31, 427-441.
31. Nagrath, S.; Sequist, L.V.; Maheswaran, S.; Bell, D.W.; Irimia, D.; Ulkus, L.; Smith, M.R.; Kwak, E.L.; Digumarthy, S.; Muzikansky, A., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450, 1235-1239.
32. Stott, S.L.; Hsu, C.H.; Tsukrov, D.I.; Yu, M.; Miyamoto, D.T.; Waltman, B.A.; Rothenberg, S.M.; Shah, A.M.; Smas, M.E.; Korir, G.K., et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. USA 2010, 107, 18392-18397.
33. Müller, V.; Riethdorf, S.; Rack, B.; Janni, W.; Fasching, P.A.; Solomayer, E.; Aktas, B.; Kasimir-Baurer, S.; Pantel, K.; Fehm, T. Prognotistic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: The DETECT study. Breast Cancer Res. 2012, 14, R118.
34. Punnoose, E.A.; Atwal, S.K.; Spoerke, J.M.; Savage, H.; Pandita, A.; Yeh, R.F.; Pirzkall, A.; Fine, B.M.; Amler, L.C.; Chen, D.S., et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010, 5, e12517.
35. Lianidou, E.S.; Markou, A. Circulating tumor cells in breast cancer: Detection systems, molecular characterization, and future challenges. Clin. Chem. 2011, 57, 1242-1255.
36. Hayashi, N.; Nakamura, S.; Tokuda, Y.; Shimoda, Y.; Yagata, H.; Yoshida, A.; Ota, H.; Hortobagyi, G.N.; Cristofanilli, M.; Ueno, N.T. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int. J. Clin. Oncol. 2012, 17, 96-104.
37. Ignatiadis, M.; Rothe, F.; Chaboteaux, C.; Durbecq, V.; Rouas, G.; Criscitiello, C.; Metallo, J.; Kheddoumi, N.; Singhal, S.K.; Michiels, S.; et al. HER2-positive circulating tumor cells in breast cancer. PLoS One 2011, 6, e15624.
38. Pestrin, M.; Bessi, S.; Galardi, F.; Truglia, M.; Biggeri, A.; Biagioni, C.; Cappadona, S.; Biganzoli, L.; Giannini, A.; di Leo, A. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 2009, 118, 523-530.
39. Riethdorf, S.; Muller, V.; Zhang, L.; Rau, T.; Loibl, S.; Komor, M.; Roller, M.; Huober, J.; Fehm, T.; Schrader, I., et al. Detection and HER2 expression of circulating tumor cells: Prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 2010, 16, 2634-2645.
40. Rossi, E.; Basso, U; Celadin, R.; Zilio, F.; Pucciarelli, S.; Aieta, M.; Barile, C.; Sava, T.; Bonciarelli, G.; Tumolo, S., et al. M30 neoepitope expression in epithelial cancer: Quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin. Cancer Res. 2010, 16, 5233-5243.
41. Meng, S.; Tripathy, D.; Shete, S.; Ashfaq, R.; Haley, B.; Perkins, S.; Beitsch, P.; Khan, A.; Euhus, D.; Osborne, C., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. USA 2004, 101, 9393-9398.
42. Van de Vijver, M.J.; Mooi, W.J.; Peterse, J.L.; Nusse, R. Amplification and over-expression of the neu oncogene in human breast carcinomas. Eur. J. Surg. Oncol. 1988, 14, 111-114.
43. Revillion, F.; Bonneterre, J.; Peyrat, J.P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer 1998, 34, 791-808.
44. Wolff, A.C.; Hammond, M.E.; Schwartz, J.N.; Hagerty, K.L.; Allred, D.C.; Cote, R.J.; Dowsett, M.; Fitzgibbons, P.L.; Hanna, W.M.; Langer, A., et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25, 118-145.
45. Hayashi, N.; Nakamura, S.; Yagata, H.; Shimoda, Y.; Ota, H.; Hortobagyi, G.N.; Cristofanilli, M.; Ueno, N.T. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: A case series. Int. J. Clin. Oncol. 2011, 16, 596-600.
46. Lankiewicz, S.; Rivero, B.G.; Bocher, O. Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Mol. Biotechnol. 2006, 34, 15-27.
47. Sieuwerts, A.M.; Mostert, B.; Bolt-de Vries, J.; Peeters, D.; de Jongh, F.E.; Stouthard, J.M.; Dirix, L.Y.; van Dam, P.A.; van Galen, A.; de Weerd, V., et al. mRNA And microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin. Cancer Res. 2011, 17, 3600-3618.
48. Fehm, T.; Muller, V.; Aktas, B.; Janni, W.; Schneeweiss, A.; Stickeler, E.; Lattrich, C.; Lohberg, C.R.; Solomayer, E.; Rack, B., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: A prospective, multicenter trial. Breast Cancer Res. Treat. 2010, 124, 403-412.
49. Aktas, B.; Tewes, M.; Fehm, T.; Hauch, S.; Kimmig, R.; Kasimir-Bauer, S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009, 11, R46.
50. Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339, 580-584.
51. Fuchs, A.B.; Romani, A.; Freida, D.; Medoro, G.; Abonnenc, M.; Altomare, L.; Chartier, I.; Guergour, D.; Villiers, C.; Marche, P.N., et al. Electronic sorting and recovery of single live cells from microlitre sized samples. Lab Chip 2006, 6, 121-126.
52. Goldhirsch, A.; Gelber, R.; Piccart-Gebhart, M.J.; de Azambuja, E.; Procter, M.; Suter, T.M.; Jackisch, C.; Cameron, D.; Weber, H.A.; Heinzmann, D., et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet 2013, 382, 1021-1028.
53. Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E., Jr.; Davidson, N.E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P.A., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1673-1684.
54. Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011, 365, 1273-1283.
55. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783-792.
56. Bempt, I.V.; van Loo, P.; Drijkoningen, M.; Neven, P.; Smeets, A.; Christiaens, M.R.; Paridaens, R.; de Wolf-Peeters, C. Polysomy 17 in breast cancer: Clinicopathologic significance and impact on HER-2 testing. J. Clin. Oncol. 2008, 26, 4869-4874.
57. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
58. Ravdin, P.M.; Chamness, G.C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review. Gene 1995, 159, 19-27.
59. Hynes, N.E.; Gerber, H.A.; Saurer, S.; Groner, B. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J. Cell Biochem. 1989, 39, 167-173.
60. Munzone, E.; Nole, F.; Goldhirsch, A.; Botteri, E.; Esposito, A.; Zorzino, L.; Curigliano, G.; Minchella, I.; Adamoli, L.; Cassatella, M.C., et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin. Breast Cancer 2010, 10, 392-397.
61. Ignatiadis, M.; Kallergi, G.; Ntoulia, M.; Perraki, M.; Apostolaki, S.; Kafousi, M.; Chlouverakis, G.; Stathopoulos, E.; Lianidou, E.; Georgoulias, V., et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res. 2008, 14, 2593-2600.
62. Wulfing, P.; Borchard, J.; Buerger, H.; Heidl, S.; Zanker, K.S.; Kiesel, L.; Brandt, B. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 2006, 12, 1715-1720.
63. Giordano, A.; Giuliano, M.; de Laurentiis, M.; Arpino, G.; Jackson, S.; Handy, B.C.; Ueno, N.T.; Andreopoulou, E.; Alvarez, R.H.; Valero, V., et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: Lack of prediction in HER2-positive disease treated with targeted therapy. Ann. Oncol. 2012, 23, 1144-1150.
64. Munzone, E.; Botteri, E.; Sandri, M.T.; Esposito, A.; Adamoli, L.; Zorzino, L.; Sciandivasci, A.; Cassatella, M.C.; Rotmensz, N.; Aurilio, G., et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin. Breast Cancer 2012, 12, 340-346.
65. Ligthart, S.T.; Bidard, F.C.; Decraene, C.; Bachelot, T.; Delaloge, S.; Brain, E.; Campone, M.; Viens, P.; Pierga, J.Y.; Terstappen, L.W. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann. Oncol. 2013, 24, 1231-1238.
66. De Albuquerque, A.; Kaul, S.; Breier, G.; Krabisch, P.; Fersis, N. Multimarker analysis of circulating tumor cells in peripheral blood of metastatic breast cancer patients: A step forward in personalized medicine. Breast Care 2012, 7, 7-12.
67. Fehm, T.; Becker, S.; Duerr-Stoerzer, S.; Sotlar, K.; Mueller, V.; Wallwiener, D.; Lane, N.; Solomayer, E.; Uhr, J. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007, 9, R74.
68. Flores, L.M.; Kindelberger, D.W.; Ligon, A.H.; Capelletti, M.; Fiorentino, M.; Loda, M.; Cibas, E.S.; Janne, P.A.; Krop, I.E. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br. J. Cancer 2010, 102, 1495-1502.
69. Somlo, G.; Lau, S.K.; Frankel, P.; Hsieh, H.B.; Liu, X.; Yang, L.; Krivacic, R.; Bruce, R.H. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res. Treat. 2011, 128, 155-163.
70. Pestrin, M.; Bessi, S.; Puglisi, F.; Minisini, A.M.; Masci, G.; Battelli, N.; Ravaioli, A.; Gianni, L.; di Marsico, R.; Tondini, C., et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res. Treat. 2012, 134, 283-289.
71. Stebbing, J.; Payne, R.; Reise, J.; Frampton, A.E.; Avery, M.; Woodley, L.; di Leo, A.; Pestrin, M.; Krell, J.; Coombes, R.C. The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: A proof-of-concept study. PLoS One 2013, 8, e62543.
72. Liu, Z.; Fusi, A.; Schmittel, A.; Tinhofer, I.; Schneider, A.; Keilholz, U. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer Biol. Ther. 2010, 10, 860-864.
73. Melcher, C.; Janni, J.W.; Schneeweiss, A.; Fasching, P.A.; Hagenbeck, C.D.; Aktas, B.; Pantel, K.; Solomayer, E.F.; Ortmann, U.; Jaeger, B.A.S.; et al. DETECT III-a multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells. Cancer Res. 2012, 72, doi: 10.1158/0008-5472.SABCS12-OT1-1-10.
74. Bidard, F.C.; Fehm, T.; Ignatiadis, M.; Smerage, J.B.; Alix-Panabieres, C.; Janni, W.; Messina, C.; Paoletti, C.; Muller, V.; Hayes, D.F. et al. Clinical application of circulating tumor cells in breast cancer: Overview of the current interventional trials. Cancer Metastasis Rev. 2013, 32, 179-188.
75. Aktas, B.A.; Muller, V.; Tewes, M.; Zeitz, J.; Kasimir-Bauer, S.; Loehberg, C.R.; Rack, B.; Schneeweiss, A.; Fehm, T. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol. Oncol. 2011, 122, 356-360.
76. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28, 1075-1083.
77. Loi, S.; Haibe-Kains, B.; Majjaj, S.; Lallemand, F.; Durbecq, V.; Larsimont, D.; Gonzalez-Angulo, A.M.; Pusztai, L.; Symmans, W.F.; Bardelli, A., et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc. Natl. Acad. Sci. USA 2010, 107, 10208-10213.
78. Schneck, H.; Blassl, C.; Meier-Stiegen, F.; Neves, R.P.; Janni, W.; Fehm, T.; Neubauer, H. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol. Oncol. 2013, 7, 976-986.
79. Pestrin, M.; Galardi, F.; Salvianti, F.; De Luca, F.; Bessi, S.; Cappacioli, G.; Gianni, A.; Di Leo, A.; Pazzagli, M.; Pinzani, P. Molecular analysis of single circulating tumor cells (CTCs) isolated from metastatic breast cancer (mBC) patients (pts). Avaiable online: http://oncologypro.esmo.org/Meeting-Resources/IMPAKT-2013/Molecular-analysis-of-single-circulating-tumor-cells-CTCs-isolated-from-metastatic-breast-cancer-mBC-patients-pts (accessed on 1 September 2013).
80. Jinno, H.; Matsuda, S.; Hayashida, T.; Takahashi, M.; Hirose, S.; Ikeda, T.; Kitagawa, Y. Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes. Chemotherapy 2012, 58, 364-370.
81. Cheng, J.P.; Yan, Y.; Wang, X.Y.; Lu, Y.L.; Yuan, Y.H.; Jia, J.; Ren, J. MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer. Chin. J. Cancer 2011, 30, 54-61.
82. Desmedt, C.; Di Leo, A.; de Azambuja, E.; Larsimont, D.; Haibe-Kains, B.; Selleslags, J.; Delaloge, S.; Duhem, C.; Kains, J.P.; Carly, B., et al. Multifactorial approach to predicting resistance to anthracyclines. J. Clin. Oncol. 2011, 29, 1578-1586.
83. Di Leo, A.; Desmedt, C.; Bartlett, J.M.; Piette, F.; Ejlertsen, B.; Pritchard, K.I.; Larsimont, D.; Poole, C.; Isola, J.; Earl, H., et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: A meta-analysis of individual patient data. Lancet Oncol. 2011, 12, 1134-1142.
84. Martin, M.; Romero, A.; Cheang, M.C.; Lopez Garcia-Asenjo, J.A.; Garcia-Saenz, J.A.; Oliva, B.; Roman, J.M.; He, X.; Casado, A.; de la Torre, J.; et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res. Treat. 2011, 128, 127-136.
85. Bonnefoi, H.; Piccart, M.; Bogaerts, J.; Mauriac, L.; Fumoleau, P.; Brain, E.; Petit, T.; Rouanet, P.; Jassem, J.; Blot, E., et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): A randomised phase 3 trial. Lancet Oncol. 2011, 12, 527-539.
86. Fernandez-Cuesta, L.; Oakman, C.; Falagan-Lotsch, P.; Smoth, K.S.; Quinaux, E.; Buyse, M.; Dolci, M.S.; Azambuja, E.D.; Hainaut, P.; Dell'orto, P., et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: Results from the BIG 02-98 phase III trial. Breast Cancer Res. 2012, 14, R70.
87. Gazzaniga, P.; Naso, G.; Gradilone, A.; Cortesi, E.; Gandini, O.; Gianni, W.; Fabbri, M.A.; Vincenzi, B.; di Silverio, F.; Frati, L., et al. Chemosensitivity profile assay of circulating cancer cells: Prognostic and predictive value in epithelial tumors. Int. J. Cancer 2010, 126, 2437-2447.
88. Gorges, T.M.; Tinhofer, I.; Drosch, M.; Rose, L.; Zollner, T.M.; Krahn, T.; von Ahsen, O. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012, 12, doi:10.1186/1471-2407-12-178.
89. Konigsberg, R.; Obermayr, E.; Bises, G.; Pfeiler, G.; Gneist, M.; Wrba, F.; de Santis, M.; Zeillinger, R.; Hudec, M.; Dittrich, C. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011, 50, 700-710.
90. Jeong, H.; Ryu, Y.J.; An, J.; Lee, Y.; Kim, A. Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 2012, 60, E87-E95.
91. Karihtala, P.; Auvinen, P.; Kauppila, S.; Haapasaari, K.M.; Jukkola-Vuorinen, A.; Soini, Y. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: Association with an aggressive tumour phenotype. Breast Cancer Res. Treat. 2013, 138, 81-90.
92. Yamashita, N.; Tokunaga, E.; Kitao, H.; Hisamatsu, Y.; Taketani, K.; Akiyoshi, S.; Okada, S.; Aishima, S.; Morita, M.; Maehara, Y. Vimentin as a poor prognostic factor for triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 2013, 139, 739-746.
93. Bitting, R.L.; Boominathan, R.; Rao, C.; Kemeny, G.; Foulk, B.; Garcia-Blanco, M.A.; Connelly, M.; Armstrong, A.J. Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods 2013, 64, 129-136.
94. Sieuwerts, A.M; Kraan, J.; Bolt, J.; van der Spoel, P.; Elstrodt, F.; Schutte, M.; Martens, J.W.; Gratama, J.W.; Sleijfer, S.; Foekens, J.A. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J. Natl. Cancer Inst. 2009, 101, 61-66.